↓ Skip to main content

Angiostatin Inhibits Bone Metastasis Formation in Nude Mice through a Direct Anti-osteoclastic Activity*

Overview of attention for article published in Journal of Biological Chemistry, September 2003
Altmetric Badge

Mentioned by

patent
1 patent

Citations

dimensions_citation
82 Dimensions

Readers on

mendeley
42 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Angiostatin Inhibits Bone Metastasis Formation in Nude Mice through a Direct Anti-osteoclastic Activity*
Published in
Journal of Biological Chemistry, September 2003
DOI 10.1074/jbc.m309024200
Pubmed ID
Authors

Olivier Peyruchaud, Claire-Marie Serre, Roisin NicAmhlaoibh, Pierrick Fournier, Philippe Clézardin

Abstract

Bone is a very common metastatic site for breast cancer. In bone metastasis, there is a vicious circle wherein bone-residing metastatic cells stimulate osteoclast-mediated bone resorption, and bone-derived growth factors released from resorbed bone promote tumor growth. The contribution of tumor angiogenesis in the growth of bone metastases is, however, unknown. By using an experimental model of bone metastasis caused by MDA-MB-231/B02 breast cancer cells that quite closely mimics the conditions likely to occur in naturally arising metastatic human breast cancers, we demonstrate here that when MDA-MB-231/B02 cells were engineered to produce at the bone metastatic site an angiogenesis inhibitor, angiostatin, there was a marked inhibition in the extent of skeletal lesions. Inhibition of skeletal lesions came with a pronounced reduction in tumor burden in bone. However, although angiostatin produced by MDA-MB-231/B02 cells was effective at inhibiting in vitro endothelial cell proliferation and in vivo angiogenesis in a Matrigel implant model, we have shown that it inhibited cancer-induced bone destruction through a direct inhibition of osteoclast activity and generation. Overall, these results indicate that, besides its well known anti-angiogenic activity, angiostatin must also be considered as a very effective inhibitor of bone resorption, broadening its potential clinical use in cancer therapy.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 42 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Germany 2 5%
Mexico 1 2%
Denmark 1 2%
Taiwan 1 2%
Unknown 37 88%

Demographic breakdown

Readers by professional status Count As %
Researcher 13 31%
Student > Ph. D. Student 7 17%
Student > Master 7 17%
Professor > Associate Professor 6 14%
Professor 2 5%
Other 8 19%
Readers by discipline Count As %
Agricultural and Biological Sciences 15 36%
Medicine and Dentistry 12 29%
Biochemistry, Genetics and Molecular Biology 5 12%
Chemistry 3 7%
Unspecified 1 2%
Other 4 10%
Unknown 2 5%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 May 2014.
All research outputs
#8,535,472
of 25,374,917 outputs
Outputs from Journal of Biological Chemistry
#32,957
of 85,240 outputs
Outputs of similar age
#18,872
of 54,016 outputs
Outputs of similar age from Journal of Biological Chemistry
#326
of 839 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 85,240 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.1. This one is in the 15th percentile – i.e., 15% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 54,016 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 839 others from the same source and published within six weeks on either side of this one. This one is in the 7th percentile – i.e., 7% of its contemporaries scored the same or lower than it.